Loading…
← CockpitCompetitor Analysis › 006280.KS GC Biopharma Corp.Open in the cockpit ↗

GC Biopharma Corp.006280.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.

Momentum leader 84
Mkt cap
$1.12B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$2.90M
20-day average traded
Fwd P/E
4.6×
forward earnings
ROIC−WACC
-3.1 pp
WACC 5.2%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · KRW₩130,800
1D-3.1%
1W-5.3%
1M-1.4%
3M+1.2%
6M-9.7%
YTD-16.9%
1Y-0.4%
ATR %3.9%
52w lowhigh28.1% off high

What GC Biopharma does

Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.

Sells vaccines largely to Korea's national immunisation programme and the private market, and plasma drugs such as immunoglobulin at home and abroad, so government purchasing and the supply of donor plasma, a scarce input, drive results. Its immunoglobulin Alyglo won US FDA approval in late 2023 and began US sales in 2024.

Products and services

  • Vaccines (flu, hepatitis, etc.)
  • Plasma-derived products (albumin, immunoglobulin)
  • Branded/generic drugs

Customers

  • Korean government (immunization programs)
  • Hospitals
  • Export markets

Where it sits in the supply chain

  • Pharmaceuticals
  • Vaccines and plasma-derived products
  • Domestic and export pharma supply

What could go right

  • Export vaccine/plasma-product demand
  • Government immunization contracts

What could go wrong

  • Plasma-supply/raw-material sourcing risk
  • Vaccine-tender pricing pressure

Moat: narrow (regulatory licence, scale, process know-how). One of few Korean makers with both vaccine and plasma-fractionation manufacturing licenses.

Headquarters: Yongin, South Korea · Founded: 1967 · Employees: 2,351

Named competitors

GC Biopharma at a glance

Size GC Biopharma (006280.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.12B, the 223rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩130,800 on 18 Nov 2026.

Performance Over six months the shares fell 9.7%, against -11.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue fell 3.0% over the last twelve months (peer median -0.9%); the operating margin is 3.6% (peer median 5.6%).

Valuation It trades at 4.6× forward earnings against a peer median of 22.7× (2nd cheapest of 13).

Capital Return on invested capital runs 3.1 points below its cost of capital (5.2% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026006280.KS 94Peer median 90
Six months, rebased to 100: GC Biopharma against the median of its 20 peers (local-currency closes).

GC Biopharma financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.88T₩1.99T₩1.68T₩1.63T₩1.71T
Revenue growth—+19%+3%-5%—
Gross profit₩522B₩536B₩468B₩459B₩561B
EBITDA₩151B₩155B₩113B₩110B₩146B
Net income₩156B-₩4.67B-₩26.3B-₩26.6B₩65.5B
Free cash flow-₩90.4B₩27.1B-₩85.5B-₩84.6B₩61.2B
Capital expenditure₩95.9B₩105B₩42.4B₩126B₩94.7B
Total debt₩848B₩982B₩828B₩724B₩576B

Quarterly statements and history in the cockpit →

GC Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%VIYASH237690CMHC300119VETO0025504547PYCMEDCL600812OMER0009896855NKTR6884436883211952BLUEJET600789006280.KS6-month return →1-month return →
Up and to the right = strong over both horizons. GC Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×VIYASH237690CMHC300119VETO0009896883211952006280.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GC Biopharma is the large dot.

GC Biopharma competitors and peer comparison

Head to head with its named competitors (006280.KS vs 302440.KS vs CSL.AX vs GRF.MC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
GC Biopharma 006280.KS$1.12B-10%-3%4%4.6×n/a
SKBS 302440.KS$2.25B-12%+11%-23%n/an/a
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%

How GC Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GC Biopharma against its 20 peers (data as of 18 Nov 2026)
Measure006280.KSPeer medianRank in peer set
1-month return-1.4%-2.3%9th highest of 21
6-month return-9.7%-11.7%10th highest of 20
Distance from 52-week high-28.1%-33.1%9th highest of 21
Revenue growth (TTM)-3.0%-0.9%8th lowest of 18
Operating margin3.6%5.6%9th lowest of 19
Forward P/E4.6×22.7×2nd cheapest of 13
ROIC minus cost of capital-3.1 pp-3.7 pp10th highest of 19
EV / EBITDA14.9×13.2×3rd most expensive of 6
Net debt / EBITDA4.5×-1.7×most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%4.6×n/an/a
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%32.2×36.3%+20.4%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%27.8×4.2%+21.7%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%418.7×n/an/a
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%18.4×3.4%-1.2%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%14.5×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%

Questions

Who are GC Biopharma's main competitors?
Named competitors: SK Bioscience (302440.KS), CSL Limited (CSL.AX), Grifols (GRF.MC). The cockpit's measured peer set (industry) also includes Symbiotec Pharmalab (SYMBIOTEC.NS), Viyash Scientific (VIYASH.NS), ST Pharm (237690.KS), Cosmo (CMHC.SW), Tianjin Ringpu Bio-technology (300119.SZ), Vetoquinol (VETO.PA).
Is GC Biopharma expensive compared with its peers?
On forward p/e it trades at 4.6× against a peer median of 22.7×, 2nd cheapest of 13 in its peer set.
How has GC Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -9.7% against -11.7% for the median peer; over one year -0.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.